by Daniel Schwartz | Dec 14, 2022 | Guidance for Patients
CLINICAL TRIALS TIPS for STARTING AN SGLT2 inhibitor SGLT2i inhibitors (eg empagliflozin, dapagliflozin, canagliflozin) have a phenomenal evidence base and have been shown to be beneficial in diabetes, heart disease (particularly heart failure) and kidney disease....
by Daniel Schwartz | Dec 10, 2022 | Healthcare IT
HEALTHCARE IT 10 Opportunities to increase access to physicians through IT efficiencies In Canada (and elsewhere) we are facing unprecedented barriers in accessing physicians (both primary care & specialty care) & other healthcare providers. Many barriers...
by Daniel Schwartz | Nov 28, 2022 | Clinical Trials, Health Policy
CLINICAL TRIALS Should patients with diabetes, CKD and proteinuria despite RAASi & SGLT2i be considered for add-on therapy with finerenone (triple therapy)? A recent Twitter thread: As a Canadian nephrologist, relevant & active national debate in light of...
by Daniel Schwartz | Nov 27, 2022 | Clinical Trials
CLINICAL TRIALS Most impactful clinical trials: slowing progression of chronic kidney disease This is a highly subjective list, but these trials have been included as they have had a meaningful impact on guidelines, patients and clinicians at a global scale. 1. IDNT:...
by Daniel Schwartz | Nov 24, 2022 | Clinical Trials
CLINICAL TRIALS 7 ways the EMPA-KIDNEY trial will impact clinical care in CKD EMPA-KIDNEY was a clinical trial testing whether taking a single pill of empagliflozin every day prevents worsening of kidney disease or deaths from heart disease in people who have chronic...
Recent Comments